Although a phase I clinical trial with PRLR neutralizing antibodies (LFA102) in breast or prostate cancer patients showed no antitumor activity when used as monotherapy [56], a lot of studies supported the rationale of using this approach in chronic inflammatory diseases like rheumatoid arthritis [57]. This evidence concerns the gene PRLR and prostate carcinoma.